Cryo-Cell International Amends Credit Agreement with Susser Bank

Cryo-Cell International ( (CCEL) ) has shared an update.

Cryo-Cell International, Inc. announced a Fifth Amendment to its Credit Agreement with Susser Bank on October 18, 2025. This amendment includes the addition of its subsidiary, Celle Corp., as a guarantor, an extension of the maturity dates for its revolving credit and term loans, and a revision of the revolving credit commitment and applicable margins. The revolving credit commitment was reduced to $8,000,000, and the maturity dates were extended to October 18, 2027, for the revolving credit and July 29, 2032, for the term loan. These changes are expected to impact the company’s financial flexibility and operational planning.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Spark’s Take on CCEL Stock

According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.

Cryo-Cell International’s overall stock score is primarily impacted by its financial performance and valuation. The company’s strong cash flow generation provides some financial flexibility, but significant balance sheet concerns and low profitability margins weigh heavily. Technical analysis offers mixed signals, while the high dividend yield is a positive aspect in an otherwise challenging valuation scenario.

To see Spark’s full report on CCEL stock, click here.

More about Cryo-Cell International

Cryo-Cell International, Inc. operates in the biotechnology industry, primarily focusing on providing stem cell cryopreservation services. The company is involved in the collection, processing, and storage of umbilical cord blood and tissue stem cells for potential future medical use.

Average Trading Volume: 16,328

Technical Sentiment Signal: Sell

Current Market Cap: $35.04M

See more insights into CCEL stock on TipRanks’ Stock Analysis page.